Stem-cell therapy

Mesenchymal stem cells (MSCs)—multipotential progenitor cells capable of self-renewal and differentiating into various lineages—represent a promising tool for regenerative medicine, tissue engineering, and cellular therapy [1, 3, 5, 7, 8]. While bone marrow was the initial source for MSC isolation, alternative sources like umbilical cord blood and adipose tissue are heavily investigated to circumvent limitations such as invasive donation procedures and the age-related decline in MSC number and differentiation potential [1]. Beyond direct differentiation, MSCs exhibit migratory abilities, secrete protective factors, and display immunoprivileged and immunomodulatory properties [7, 8].

Despite their therapeutic potential, significant challenges remain regarding cell sourcing, in vitro expansion, and replicative senescence [10]. Replicative senescence during culture limits the potency and consistency of MSCs, prompting the development of strategies like partial reprogramming—such as novel circRNA platforms designed to rejuvenate aged MSCs without unintended pluripotent conversion [10]. Other open avenues include optimizing engineered tissue alternatives to conventional bone grafts [2] and utilizing human umbilical cord MSC-derived exosomes loaded with compounds like pterostilbene to enhance neuroprotection and targeted delivery across the blood-brain barrier [9]. Additionally, distinct from therapeutic adult MSCs, cancer stem cells (CSCs) are targeted in oncology due to their driving role in tumor recurrence, metastasis, and resistance [4].